Imatinib mesylate (gleevec) hepatotoxicity

Dig Dis Sci. 2007 Feb;52(2):598-601. doi: 10.1007/s10620-006-9117-1. Epub 2007 Jan 12.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alanine Transaminase / blood
  • Alkaline Phosphatase / blood
  • Antineoplastic Agents / adverse effects*
  • Aspartate Aminotransferases / blood
  • Benzamides
  • Bilirubin / blood
  • Blood Cell Count
  • Erythrocyte Indices
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Liver Failure / blood
  • Liver Failure / chemically induced*
  • Liver Failure / pathology
  • Male
  • Necrosis
  • Piperazines / adverse effects*
  • Protein Kinase Inhibitors / adverse effects*
  • Prothrombin Time
  • Pyrimidines / adverse effects*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Alkaline Phosphatase
  • Bilirubin